oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells
Department of Medicine, Örebro Medical Center Hospital, Örebro, Sweden.
Department of Hematology, Huddinge Uniersity Hospital, Huddinge, Sweden.
Department of Pathology, Örebro Medical Center Hospital, Örebro, Sweden.
Department of Pathology, Örebro Medical Center Hospital, Örebro, Sweden.
Show others and affiliations
2001 (English)In: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 25, no 11, p. 961-966Article in journal (Refereed) Published
Abstract [en]

Topoisomerase IIalpha (topoII alpha) is the target enzyme for several antineoplastic drugs. Correlation between low expression of topo IIalpha and drug resistance has been shown in vitro, but there is limited evidence of a correlation to initial response to treatment or to overall prognosis. Normal cells express topo IIalpha in S/G2/M phase of the cell cycle but not in G0/G1 phase. However, some data suggest that topo IIalpha could be expressed in G0/G1 phase in malignant cells. We have investigated the expression of topo IIalpha in leukemic cells from 25 patients with acute leukemia by flow cytometry, separating cells of different cell cycle phases. We demonstrated that 9/25 samples showed >50% positive cells in G0/G1, and another five samples showed >20%. This finding could possibly provide an explanation to previous difficulties in correlating topo IIalpha expression with clinical outcome. Six of eight patients, where >20% of the cells in G0/G1 were positive for topo IIalpha, entered CR, compared to one of five patients with <20% topo IIalpha positive cells in G0/G1. We suggest that topo IIalpha expression in G0/G1 in leukemic cells may be of predictive value for clinical response to cytostatic drugs.

Place, publisher, year, edition, pages
Oxford, United Kingdom: Elsevier, 2001. Vol. 25, no 11, p. 961-966
Keywords [en]
Acute leukemia, topoisomerase IIalpha, drug resistance, flow cytometry, cell cycle
National Category
Cancer and Oncology Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:oru:diva-49518DOI: 10.1016/S0145-2126(01)00062-5ISI: 000171788800005PubMedID: 11597731Scopus ID: 2-s2.0-0034740798OAI: oai:DiVA.org:oru-49518DiVA, id: diva2:914887
Available from: 2016-03-27 Created: 2016-03-25 Last updated: 2017-11-30Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Uggla, BertilKarlsson, Mats G.Tidefelt, Ulf

Search in DiVA

By author/editor
Uggla, BertilKarlsson, Mats G.Tidefelt, Ulf
In the same journal
Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis
Cancer and OncologyClinical Laboratory Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 0 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf